Search
Azelnidipine
go.drugbank.com/drugs/DB09230InvestigationalAzelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. … It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers [L1379].
LIC-477
go.drugbank.com/drugs/DB05363ExperimentalLIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.
Mimosine
go.drugbank.com/drugs/DB01055ExperimentalMimosine is an antineoplastic alanine-substituted pyridine derivative isolated from _Leucena glauca_.
Clioquinol
go.drugbank.com/drugs/DB04815ApprovedVet approvedWithdrawnClioquinol was withdrawn in 1983 due to neurotoxicity.
Alethine
go.drugbank.com/drugs/DB05800InvestigationalIt is a low molecular weight disulfide that has been shown to exhibit in vivo antitumor activity in murine myeloma and melanoma models. … Alethine is studied in the treatment of cancer. It belongs to a family of chemicals called disulfides.
Resatorvid
go.drugbank.com/drugs/DB05943InvestigationalResatorvid is an investigational compound designed for the treatment of severe sepsis.
Mitemcinal
go.drugbank.com/drugs/DB06587InvestigationalMitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.
Ichthammol
go.drugbank.com/drugs/DB11341ApprovedIt is available in OTC products as an active ingredient for the treatment of skin disorders such as eczema, psoriasis and boils as it is thought to exhibit anti-inflammatory, antibacterial and antimycotic … It is an ammonium salt of dark sulfonated shale oil (bituminous schists) produced via distillation of the oil followed by sulfonation and neutralization.
Products: SCHWARZE SALBE 20% LICHT N, SCHWARZE SALBE 50% LICHT NAfelimomab
go.drugbank.com/drugs/DB04956ExperimentalAfelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.